Blood-based detection of pTau181 could identify pathological Alzheimer’s disease

Written by Sharon Salt, Senior Editor

UPDATED – 23 April 2020 – blood pTau181 as a biomarker for Alzheimer’s A recent study from The Lancet Neurology has indicated that levels of pTau181 are greatly elevated in the early stage of Alzheimer’s, also known as mild cognitive impairment. However, the study reports that this this elevated level was only observed in individuals who also had amyloid plaques (as revealed by PET).  According to the team, the level of specific pTau181 in blood plasma also corresponded with the level of tau tangles in the brain registered with the PET technique. The blood test also identified people early on...

To view the full article, please register now for access

It's completely free